Parallel 6’s end-to-end patient recruitment, engagement and retention solution, Clinical 6™ increases security and privacy of patient information during Clinical Trials

By September 10, 2015Press Releases

FOR IMMEDIATE RELEASE

Contact:

Aimee Eucce

aeucce@parallel6.com

858-205-8577

 

Parallel 6’s end-to-end patient recruitment, engagement and retention solution, Clinical 6™ increases security and privacy of patient information during Clinical Trials

Clinical 6™ is an end-to-end patient centric platform enabling enrollment, engagement, ePRO, and reporting for clinical trials worldwide.

Parallel 6, an enterprise mobile technology company, announced today that Clinical 6™, its end-to-end patient engagement platform, has been upgraded to a security posture that has upheld scrutiny in the highest levels of the United States government as it was rolled out across several government agencies.  The Clinical Reach platform is designed to encrypt data, from the patient’s internet enabled device to the Clinical Reach platform whether residing on platform or transitioning further to other systems of record.  The ReachLink module facilitates secure transport at every stage whether to a handset solution, a 3rd party system, a health record, or a simple import/export validation, and approval process.

Through Clinical 6™, Parallel6 is leading the effort to translate digital technologies into treatments and diagnostics for patients. Their goal is to replace multiple patient centric systems with a single cloud based enterprise platform. This means streamlined development processes and faster deployment for clinical trial stakeholders.

“We are at the dawn of harnessing the power of digital technology in clinical research,” said Allan Camaisa, CEO and Chairman of Parallel 6. “Clinical 6™ and multi-factor authentication will provide new opportunities to connect with patients worldwide while securely enabling communication channels that positively affect clinical trial participation and results.”

This year, Clinical 6™ successfully launched a security and privacy strategy to ensure potential participants and providers such as sponsors, CRO’s, PIs, and local IRBs are confident that patient and other important data is protected.  This includes the data that resides on the participants internet enabled device and the transmission of this data to the Clinical Reach platform.

“With the click of a button, clinical trial stakeholders can securely engage with participants in real-time through surveys, appointment reminders, medication adherence reminders and other trial specific information using any internet enabled device. Clinical 6™ is among the first of its kind, harnessing state of the art technology to bring to both providers and participants of clinical trials,” commented David Turner, President, CTO and Founder of Parallel 6.

The Clinical 6™ platform also gives providers the ability to securely view trial specific information, medication adherence reports, and ePRO in real-time. Now providers have immediate access to the data they need to make informed decisions, faster.  Clinical Reach leads to better outcomes and improved health.

###

About Parallel 6

Parallel 6, is an innovator in enterprise cloud-based technologies. Clinical 6™, a Parallel 6 product, is an end-to-end patient centric engagement platform for the healthcare and life sciences industries. Clinical Reach enables clinical trial stakeholders to digitally recruit, eQualify, eConsent and engage clinical trial participants through their patented platform. Additional solutions include GovReach for government agencies and Captive Reach for corporate organizations that influence consumer behavior, enhance brand recognition and build strong, client-customer relationships through push notifications, gamification strategies and more. The firm is headquartered in San Diego with federal offices in Washington D.C. For more information, visit http://www.parallel6.com/.

About Kamei Triebell